A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I Hormone Sensitive HER2-Negative Oncotype Recurrence Score 18 Breast Cancer (DEBRA* DE-escalation of Breast RAdiation)

Brief description of study

Comparison of endocrine therapy alone (experimental arm) vs breast radiation and endocrine therapy (SOC) in hormone-sensitive, stage 1 breast cancer post lumpectomy. Oncotype Recurrence Score must be less than or equal to 18 in order to participate. The experimental arm will be tested for non-inferiority. HRQOL will be collected with several PRO assessment tools. Subjects will have option to supply blood and left-over tumor tissue for biobank and correlative studies.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

Updated on 12 Apr 2023. Study ID: 852693

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).